Open Access Highly Accessed Review

SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery

Davide Bedognetti123*, James M Balwit1, Ena Wang12, Mary L Disis14, Cedrik M Britten5, Lucia G Delogu16, Sara Tomei127, Bernard A Fox18, Thomas F Gajewski19, Francesco M Marincola12 and Lisa H Butterfield110

Author Affiliations

1 Society for Immunotherapy of Cancer, Milwaukee, WI, USA

2 Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA

3 Department of Internal Medicine (DiMI), University of Genoa, and Department of Medical Oncology, National Cancer Research Institute of Genoa, Genoa, Italy

4 Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle, WA, USA

5 Department of Medicine, University Medical Center of the Johannes Gutenberg-University, and Ribological GmbH, Mainz, Germany, Department of Internal Medicine, University Medical Center of the Johannes Gutenberg-University, and Clinical Development, BioNTech AG, Mainz, Germany

6 University of Sassari, Department of Drug Sciences, Sassari, Italy

7 Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, University of Pisa and Pisa University Hospital, Pisa, Italy

8 Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA

9 Section of Hematology/Oncology, Department of Pathology and Department of Medicine, University of Chicago, Chicago, IL, USA

10 Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA

For all author emails, please log on.

Journal of Translational Medicine 2011, 9:155  doi:10.1186/1479-5876-9-155

Published: 19 September 2011

Abstract

Recent positive clinical results in cancer immunotherapy point to the potential of immune-based strategies to provide effective treatment of a variety of cancers. In some patients, the responses to cancer immunotherapy are durable, dramatically extending survival. Extensive research efforts are being made to identify and validate biomarkers that can help identify subsets of cancer patients that will benefit most from these novel immunotherapies. In addition to the clear advantage of such predictive biomarkers, immune biomarkers are playing an important role in the development, clinical evaluation and monitoring of cancer immunotherapies. This Cancer Immunotherapy Resource Document, prepared by the Society for Immunotherapy of Cancer (SITC, formerly the International Society for Biological Therapy of Cancer, iSBTc), provides key references and online resources relevant to the discovery, evaluation and clinical application of immune biomarkers. These key resources were identified by experts in the field who are actively pursuing research in biomarker identification and validation. This organized collection of the most useful references, online resources and tools serves as a compass to guide discovery of biomarkers essential to advancing novel cancer immunotherapies.